Get the Stockscreener App
173.94
0.86%
1.49
After Hours:
173.94
Icon Plc stock is traded at $173.94, with a volume of 818.59K.
It is up +0.86% in the last 24 hours and up +6.61% over the past month.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
See More
Previous Close:
$172.45
Open:
$173.51
24h Volume:
818.59K
Relative Volume:
1.00
Market Cap:
$13.42B
Revenue:
$8.27B
Net Income/Loss:
$173.28M
P/E Ratio:
80.11
EPS:
2.1712
Net Cash Flow:
$785.90M
1W Performance:
+9.05%
1M Performance:
+6.61%
6M Performance:
+78.20%
1Y Performance:
+0.47%
1-Day Range:
$172.09
$175.59
1-Week Range:
$156.70
$175.63
52-Week Range:
$66.57
$203.91
Icon Plc Stock (ICLR) Company Profile
Compare ICLR vs TMO, DHR, NTRA, IQV, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
173.94 | 13.06B | 8.27B | 173.28M | 785.90M | 2.1712 |
TMO
Thermo Fisher Scientific Inc
|
648.43 | 225.48B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
208.36 | 140.70B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
345.34 | 47.41B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
268.82 | 43.09B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
153.69 | 41.42B | 7.23B | 1.41B | 1.09B | 4.979 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-23-26 | Upgrade | Jefferies | Hold → Buy |
| Feb-18-26 | Upgrade | TD Cowen | Hold → Buy |
| Feb-17-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Feb-12-26 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-12-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-08-26 | Downgrade | Truist | Buy → Hold |
| Dec-15-25 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-13-25 | Initiated | BMO Capital Markets | Market Perform |
| Sep-09-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-03-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Aug-21-25 | Downgrade | Citigroup | Buy → Neutral |
| Jul-24-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-29-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Jan-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Neutral |
| Sep-18-24 | Initiated | Leerink Partners | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| Dec-15-23 | Initiated | Truist | Buy |
| Sep-13-23 | Initiated | TD Cowen | Outperform |
| Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-07-22 | Initiated | UBS | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-21 | Initiated | Citigroup | Neutral |
| Apr-13-21 | Resumed | BofA Securities | Neutral |
| Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-03-21 | Initiated | Barclays | Equal Weight |
| Mar-01-21 | Upgrade | UBS | Neutral → Buy |
| Feb-26-21 | Upgrade | Truist | Hold → Buy |
| Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-26-19 | Upgrade | UBS | Sell → Neutral |
| Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-09-18 | Initiated | UBS | Sell |
| Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-18 | Reiterated | Mizuho | Neutral |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
| Oct-27-17 | Reiterated | Barclays | Equal Weight |
| Sep-11-17 | Initiated | BofA/Merrill | Buy |
| Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
| Jul-27-17 | Reiterated | Mizuho | Neutral |
| Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
ICON plc Stock Price: ICLR Stock Chart, Market Cap & News Today - CoinGecko
Hybrid Clinical Research Associate Job at ICON | Apply Online Here - BioTecNika
A Look at Icon PLC (ICLR) After 3.9% Gain -- GF Value $207.68 vs Price $165.69 - GuruFocus
ICON PLC (NASDAQ: ICLR) Releases Unaudited Interim Financial Statements in September 9 Filing - Kalkine Media
ICON taps Anthropic and Microsoft as it puts clinical-trial agents into production - R&D World
Is Icon PLC (ICLR) a Bargain After 4.1% Drop? GF Value Says Unde - GuruFocus
ICON plc (ICLR) Stock Report: Evaluating a 12.56% Potential Upside Amidst Healthcare Sector Expansion - DirectorsTalk Interviews
CVS Health (CVS) Up 1% Since Last Earnings Report: Can It Continue? - Zacks Investment Research
Long term debt to total equity ratio of ICON Plc – HAM:IJF - TradingView
Icon plc stock holds steady as Q2 2026 results support full-year guidance - ad-hoc-news.de
ICON Plc (ICLR) Stock Analysis: Exploring Growth Potential With A 9.14% Upside - DirectorsTalk Interviews
ICON plcADR Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
How ICON’s Mixed Q1 Earnings and Reaffirmed 2026 Outlook Could Impact ICON (ICLR) Investors - sahmcapital.com
Icon PLC (ICLR) Up 2.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Icon (ICLR) Stock Forecast and Price Target 2026 $ICLR - MarketBeat
ICON plc (ICLR) Stock Analysis: Navigating Growth in Diagnostics & Research with a 7.74% Upside - DirectorsTalk Interviews
ICON Releases 2025 ICON Cares Report, Highlighting Progress in Patient Impact, Innovation and Sustainability - BioSpace
ICON plc (ICLR) posts top-1% ESG score and 73% emissions cut - Stock Titan
A Look at Icon PLC (ICLR) After 3.2% Gain -- GF Value $208.22 vs Price $172.49 - GuruFocus
ETFs Investing in ICON Plc Stocks - TradingView
ICON plc (NASDAQ: ICLR) swaps secured loans for $2.15B in new notes - Stock Titan
White & Case advises ICON on its US$2.15 billion notes offering and related secured debt refinancing - White & Case LLP
6-K: Icon PLC | 6-K: Report of foreign private issuer (related to financial reporting) - Moomoo
Icon PLC (ICLR) Shares Surge 3.9% -- What GF Score of 93 Tells I - GuruFocus
ICON plc (ICLR) Stock Analysis: Strong Buy Ratings and 13.74% Potential Upside Highlight Investment Appeal - DirectorsTalk Interviews
Icon CEO awarded $3.7m in shares as company emerges from turmoil - Irish Independent
Does ICON’s Shift to an Unsecured Capital Structure Reshape the Bull Case for ICLR? - Sahm
Icon Plc $ICLR Shares Bought by Handelsbanken Fonder AB - MarketBeat
Invesco Ltd. (ICLR) discloses 6.9% beneficial stake in ICON PLC - Stock Titan
Director Of Icon Makes $138K Sale - Benzinga
ICON plc (ICLR) Rises 0.96% to $167.17 on Steady CRO Sector DemandInstitutional Buy Signals - vinanet.vn
Trinity Street Asset Management LLP Raises Stock Position in Icon Plc $ICLR - MarketBeat
ICON prices $2.15B in notes to refinance secured debt - Dealroom
ICON PLC (ICLR) director logs RSU vesting, new grant and tax sell-to-cover trades - Stock Titan
ICON plc (ICLR) director’s RSU vesting triggers tax-related share sales - Stock Titan
ICON PLC (ICLR) director sells 2,677 shares, receives new 2,047 RSU grant - Stock Titan
ICON PLC (ICLR) director sells 841 shares to cover RSU taxes, gets new grant - Stock Titan
ICON PLC (ICLR) director reports RSU vesting, new grant and tax sell-to-cover sales - Stock Titan
ICON PLC (ICLR) awards 5,886 restricted share units to Chief Accounting Officer - Stock Titan
ICON PLC (ICLR) director Linda Grais sells shares to cover taxes, gets new RSU grant - Stock Titan
ICON plc (ICLR) director Climax details RSU vesting, new grant and tax sell-to-cover trades - Stock Titan
ICON plc (ICLR) CFO gets new RSUs, options and sells shares for taxes - Stock Titan
ICON PLC (ICLR) awards 1,324 Restricted Share Units to director Kevin Francis Egan - Stock Titan
Edward Barry Balfe Decides To Exercise Options At Icon Worth $0 - benzinga.com
FMR LLC Buys Icon PLC (ICLR) -- Shares Look 21% Undervalued on G - GuruFocus
ICON plc (ICLR) investor files to sell 915 restricted shares under Rule 144 - Stock Titan
ICON plc (NASDAQ: ICLR) holder plans $138K sale of vested shares - Stock Titan
ICLR (ICLR) shareholder files to sell 841 vested shares on NASDAQ - Stock Titan
ICON plc (NASDAQ: ICLR) holder files Form 144 to sell 841 shares - Stock Titan
ICLR shareholder plans sale of 841 common shares | ICLR SEC FilingForm 144 - Stock Titan
ICON plc (ICLR) holder files notice to sell 841 vested shares on NASDAQ - Stock Titan
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Icon Plc Stock (ICLR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| O'Neill Julie | Director |
Aug 11 '26 |
Sale |
164.29 |
915 |
150,326 |
3,515 |
| Murray Ciaran | Director |
Aug 11 '26 |
Sale |
164.29 |
2,677 |
439,803 |
20,452 |
| Murphy Ronan Martin | Director |
Aug 11 '26 |
Sale |
164.29 |
841 |
138,168 |
3,847 |
| McCague Eugene Pacelli | Director |
Aug 11 '26 |
Sale |
164.29 |
841 |
138,168 |
3,811 |
| Grais Linda | Director |
Aug 11 '26 |
Sale |
164.29 |
841 |
138,169 |
6,162 |
| CLIMAX JOHN DR | Director |
Aug 11 '26 |
Sale |
164.29 |
841 |
138,168 |
2,087 |
| Clerkin Nigel Bernard John | Chief Financial Officer |
Aug 11 '26 |
Sale |
164.29 |
2,267 |
372,445 |
5,881 |
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):